Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Court says ruling on Biogen's Tecfidera request will stand, Bloomberg reports » 11:52
06/24/20
06/24
11:52
06/24/20
11:52
BIIB

Biogen

$264.00 /

-4.4 (-1.64%)

The U.S. Court of Appeals…

The U.S. Court of Appeals for the Federal Circuit decided to decline a Biogen request to reconsider its earlier ruling that prevented Biogen from delaying Banner Life Sciences's rival to its multiple sclerosis drug Tecfidera, reported Bloomberg. "In April, U.S. Court of Appeals for the Federal Circuit ruled that an extension given to Biogen's patent on the treatment only covers the active ingredient, not a related molecule given at a different dosage," added the Bloomberg story. Reference Link

ShowHide Related Items >><<
BIIB Biogen
$264.00 /

-4.4 (-1.64%)

BIIB Biogen
$264.00 /

-4.4 (-1.64%)

06/22/20 RBC Capital
Biogen price target lowered to $273 from $303 at RBC Capital
06/22/20 Barclays
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties'
06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
BIIB Biogen
$264.00 /

-4.4 (-1.64%)

BIIB Biogen
$264.00 /

-4.4 (-1.64%)

BIIB Biogen
$264.00 /

-4.4 (-1.64%)

BIIB Biogen
$264.00 /

-4.4 (-1.64%)

Conference/Events
SVB Leerink to hold a virtual forum » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
AXSM

Axsome Therapeutics

$78.97 /

+0.44 (+0.56%)

, BIIB

Biogen

$268.40 /

+4.05 (+1.53%)

, GWPH

GW Pharmaceuticals

$125.00 /

-0.89 (-0.71%)

, ITCI

Intra-Cellular

$26.69 /

+1.035 (+4.04%)

, MRNS

Marinus Pharmaceuticals

$2.74 /

+0.1 (+3.80%)

2nd Annual CNS Virtual…

2nd Annual CNS Virtual Event will be held on June 23-24.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.74 /

+0.1 (+3.80%)

ITCI Intra-Cellular
$26.69 /

+1.035 (+4.04%)

GWPH GW Pharmaceuticals
$125.00 /

-0.89 (-0.71%)

BIIB Biogen
$268.40 /

+4.05 (+1.53%)

AXSM Axsome Therapeutics
$78.97 /

+0.44 (+0.56%)

AXSM Axsome Therapeutics
$78.97 /

+0.44 (+0.56%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
BIIB Biogen
$268.40 /

+4.05 (+1.53%)

06/22/20 RBC Capital
Biogen price target lowered to $273 from $303 at RBC Capital
06/22/20 Barclays
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties'
06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
GWPH GW Pharmaceuticals
$125.00 /

-0.89 (-0.71%)

06/01/20 Oppenheimer
GW Pharmaceuticals assumed with an Outperform at Oppenheimer
05/14/20 Cantor Fitzgerald
GW Pharmaceuticals price target raised to $154 from $120 at Cantor Fitzgerald
04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
ITCI Intra-Cellular
$26.69 /

+1.035 (+4.04%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
MRNS Marinus Pharmaceuticals
$2.74 /

+0.1 (+3.80%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.74 /

+0.1 (+3.80%)

ITCI Intra-Cellular
$26.69 /

+1.035 (+4.04%)

GWPH GW Pharmaceuticals
$125.00 /

-0.89 (-0.71%)

BIIB Biogen
$268.40 /

+4.05 (+1.53%)

AXSM Axsome Therapeutics
$78.97 /

+0.44 (+0.56%)

BIIB Biogen
$268.40 /

+4.05 (+1.53%)

BIIB Biogen
$268.40 /

+4.05 (+1.53%)

AXSM Axsome Therapeutics
$78.97 /

+0.44 (+0.56%)

GWPH GW Pharmaceuticals
$125.00 /

-0.89 (-0.71%)

BIIB Biogen
$268.40 /

+4.05 (+1.53%)

AXSM Axsome Therapeutics
$78.97 /

+0.44 (+0.56%)

Conference/Events
SVB Leerink to hold a virtual forum » 09:54
06/23/20
06/23
09:54
06/23/20
09:54
AXSM

Axsome Therapeutics

$78.53 /

+ (+0.00%)

, BIIB

Biogen

$266.50 /

+2.15 (+0.81%)

, GWPH

GW Pharmaceuticals

$126.50 /

+0.61 (+0.48%)

, ITCI

Intra-Cellular

$25.89 /

+0.24 (+0.94%)

, MRNS

Marinus Pharmaceuticals

$2.67 /

+0.035 (+1.33%)

2nd Annual CNS Virtual…

2nd Annual CNS Virtual Event will be held on June 23-24.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.67 /

+0.035 (+1.33%)

ITCI Intra-Cellular
$25.89 /

+0.24 (+0.94%)

GWPH GW Pharmaceuticals
$126.50 /

+0.61 (+0.48%)

BIIB Biogen
$266.50 /

+2.15 (+0.81%)

AXSM Axsome Therapeutics
$78.53 /

+ (+0.00%)

AXSM Axsome Therapeutics
$78.53 /

+ (+0.00%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
BIIB Biogen
$266.50 /

+2.15 (+0.81%)

06/22/20 RBC Capital
Biogen price target lowered to $273 from $303 at RBC Capital
06/22/20 Barclays
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties'
06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
GWPH GW Pharmaceuticals
$126.50 /

+0.61 (+0.48%)

06/01/20 Oppenheimer
GW Pharmaceuticals assumed with an Outperform at Oppenheimer
05/14/20 Cantor Fitzgerald
GW Pharmaceuticals price target raised to $154 from $120 at Cantor Fitzgerald
04/08/20 Northland
GW Pharmaceuticals initiated with an Outperform at Northland
03/06/20 Citi
Citi starts GW Pharmaceuticals at Buy, says recent pullback overdone
ITCI Intra-Cellular
$25.89 /

+0.24 (+0.94%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
MRNS Marinus Pharmaceuticals
$2.67 /

+0.035 (+1.33%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.67 /

+0.035 (+1.33%)

ITCI Intra-Cellular
$25.89 /

+0.24 (+0.94%)

GWPH GW Pharmaceuticals
$126.50 /

+0.61 (+0.48%)

BIIB Biogen
$266.50 /

+2.15 (+0.81%)

AXSM Axsome Therapeutics
$78.53 /

+ (+0.00%)

BIIB Biogen
$266.50 /

+2.15 (+0.81%)

ITCI Intra-Cellular
$25.89 /

+0.24 (+0.94%)

BIIB Biogen
$266.50 /

+2.15 (+0.81%)

AXSM Axsome Therapeutics
$78.53 /

+ (+0.00%)

GWPH GW Pharmaceuticals
$126.50 /

+0.61 (+0.48%)

BIIB Biogen
$266.50 /

+2.15 (+0.81%)

AXSM Axsome Therapeutics
$78.53 /

+ (+0.00%)

Recommendations
Biogen price target lowered to $273 from $303 at RBC Capital » 08:35
06/22/20
06/22
08:35
06/22/20
08:35
BIIB

Biogen

$270.95 /

+10.28 (+3.94%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams lowered the firm's price target on Biogen to $273 from $303 and keeps a Sector Perform rating on the shares. The analyst notes that following his discussion with a patent litigation expert and last week's status conference call, he believes that there is little that the company will be able to do to stop generic Tecfidera entry in the near-term - "perhaps even by 2021." Abrahams anticipates more volatility in Biogen shares as additional litigation developments emerge throughout the summer, stating that he prefers to remain on the sidelines.

ShowHide Related Items >><<
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

06/22/20 Barclays
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties'
06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
06/19/20 Credit Suisse
Biogen price target lowered to $270 from $310 at Credit Suisse
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

Downgrade
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties' » 06:02
06/22/20
06/22
06:02
06/22/20
06:02
BIIB

Biogen

$270.95 /

+10.28 (+3.94%)

Barclays analyst Carter…

Barclays analyst Carter Gould downgraded Biogen to Equal Weight from Overweight with a price target of $280, down from $370. The district court decision that invalidated a key Tecfidera patent raises the likely prospect of generics launching in 2021, threatening a third of Biogen's free cash flow and "notably shifting the valuation discussion" before consideration of aducanumab optionality, Gould tells investors in a research note titled "Mounting Uncertainties." The downside scenario of Tecfidera generics and aducanumab not being approved could compress Biogen's earnings per share power to $20-$24 in 2021/22 from 2020 estimates of ~$32, says the analyst. While successful filing, acceptance, and Priority Review of aducanumab could see the stock reset to $330-$350, conviction has "waned in the wake of delays and a lack of clarity around points of discussion with FDA, adds Gould.

ShowHide Related Items >><<
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
06/19/20 Credit Suisse
Biogen price target lowered to $270 from $310 at Credit Suisse
06/19/20 Piper Sandler
Biogen price target lowered to $260 from $307 at Piper Sandler
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

Downgrade
Biogen downgraded to Equal Weight from Overweight at Barclays » 05:54
06/22/20
06/22
05:54
06/22/20
05:54
BIIB

Biogen

$270.95 /

+10.28 (+3.94%)

Barclays analyst Carter…

Barclays analyst Carter Gould downgraded Biogen to Equal Weight from Overweight with a $280 price target.

ShowHide Related Items >><<
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
06/19/20 Credit Suisse
Biogen price target lowered to $270 from $310 at Credit Suisse
06/19/20 Piper Sandler
Biogen price target lowered to $260 from $307 at Piper Sandler
06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

BIIB Biogen
$270.95 /

+10.28 (+3.94%)

Recommendations
Biogen patent loss a 'major setback,' says Citi » 06:31
06/19/20
06/19
06:31
06/19/20
06:31
BIIB

Biogen

$260.67 /

-20.89 (-7.42%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal views Biogen's Tecfidera patent loss yesterday as a "major setback," noting the drug contributes $60 per share to his discounted cash flow model. However, the stock may not move all the way down $60 because Biogen will likely appeal, the stock has been a little weak for last few days accounting for some risk, and investor focus is still on Aducanumab which could limit the downside, Bansal tells investors in a research note. However, the analyst views the ruling as a surprise and keeps a Sell rating on Biogen.

ShowHide Related Items >><<
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

06/19/20 Credit Suisse
Biogen price target lowered to $270 from $310 at Credit Suisse
06/19/20 Piper Sandler
Biogen price target lowered to $260 from $307 at Piper Sandler
06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Piper Sandler
Piper 'incrementally cautious' on Biogan after 'famed' patent ruled invalid
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

Recommendations
Biogen price target lowered to $270 from $310 at Credit Suisse » 06:31
06/19/20
06/19
06:31
06/19/20
06:31
BIIB

Biogen

$260.67 /

-20.89 (-7.42%)

Credit Suisse analyst…

Credit Suisse analyst Evan Seigerman lowered the firm's price target on Biogen to $270 from $310 and keeps a Neutral rating on the shares after a court ruled that a key Tecfidera patent is invalid, potentially allowing for generic competition as early as 2H20. While the appeals process and court decision could delay the launch of a generic, Seigerman thinks the franchise is at high risk for direct generic competition.

ShowHide Related Items >><<
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

06/19/20 Piper Sandler
Biogen price target lowered to $260 from $307 at Piper Sandler
06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Piper Sandler
Piper 'incrementally cautious' on Biogan after 'famed' patent ruled invalid
06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

Recommendations
Biogen price target lowered to $260 from $307 at Piper Sandler » 05:02
06/19/20
06/19
05:02
06/19/20
05:02
BIIB

Biogen

$260.67 /

-20.89 (-7.42%)

, ALKS

Alkermes

$17.74 /

+0.68 (+3.99%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond lowered the firm's price target on Biogen (BIIB) to $260 from $307 and keeps a Neutral rating on the shares. The analyst says his survey of 103 neurologists indicates that, regardless of the timing of Tecfidera's loss of exclusivity, the "winds of competitive change" in the multiple sclerosis market do not favor Biogen. He sees "strong evidence" that doctors are not buying the value proposition around Vumerity, a drug partnered with Alkermes (ALKS). Further, Biogen's fumarate franchise is increasingly vulnerable to newer options, even beyond Ocrevus, Raymond tells investors in a research note. The analyst remains "meaningfully below consensus" for Tecfidera and Vumerity, and continues to believe more certainty around a near-term loss of exclusivity for Tecfidera could make for additional downside to the stock.

ShowHide Related Items >><<
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

ALKS Alkermes
$17.74 /

+0.68 (+3.99%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Piper Sandler
Piper 'incrementally cautious' on Biogan after 'famed' patent ruled invalid
06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
06/09/20
Fly Intel: Top five analyst downgrades
ALKS Alkermes
$17.74 /

+0.68 (+3.99%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
BIIB Biogen
$260.67 /

-20.89 (-7.42%)

ALKS Alkermes
$17.74 /

+0.68 (+3.99%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

ALKS Alkermes
$17.74 /

+0.68 (+3.99%)

BIIB Biogen
$260.67 /

-20.89 (-7.42%)

On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:35
06/18/20
06/18
16:35
06/18/20
16:35
SPOT

Spotify

$225.35 /

+25.51 (+12.77%)

, BIIB

Biogen

$260.30 /

-21.26 (-7.55%)

, MYL

Mylan

$16.35 /

+0.39 (+2.44%)

, KR

Kroger

$31.87 /

-0.945 (-2.88%)

, CCL

Carnival

$18.85 /

-0.24 (-1.26%)

, HTZ

Hertz

$1.81 /

-0.195 (-9.75%)

, FB

Facebook

$235.94 /

+0.23 (+0.10%)

, ENPH

Enphase Energy

$45.69 /

+6.68 (+17.12%)

, T

AT&T

$30.34 /

+0.08 (+0.26%)

, X

U.S. Steel

$8.17 /

-1.2 (-12.81%)

, HUD

Hudson

$5.79 /

-0.43 (-6.91%)

Stocks finished near flat…

Open Full Text

ShowHide Related Items >><<
X U.S. Steel
$8.17 /

-1.2 (-12.81%)

T AT&T
$30.34 /

+0.08 (+0.26%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

MYL Mylan
$16.35 /

+0.39 (+2.44%)

KR Kroger
$31.87 /

-0.945 (-2.88%)

HUD Hudson
$5.79 /

-0.43 (-6.91%)

HTZ Hertz
$1.81 /

-0.195 (-9.75%)

FB Facebook
$235.94 /

+0.23 (+0.10%)

ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

CCL Carnival
$18.85 /

-0.24 (-1.26%)

BIIB Biogen
$260.30 /

-21.26 (-7.55%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

06/19/20 Monness Crespi
Spotify price target raised to $275 from $200 at Monness Crespi
05/28/20
Fly Intel: Top five analyst downgrades
05/28/20 Redburn
Spotify downgraded to Neutral from Buy at Redburn
05/20/20 JPMorgan
Spotify deal with Joe Rogan could be 'game-changer,' says JPMorgan
BIIB Biogen
$260.30 /

-21.26 (-7.55%)

06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
06/19/20 Credit Suisse
Biogen price target lowered to $270 from $310 at Credit Suisse
06/19/20 Piper Sandler
Biogen price target lowered to $260 from $307 at Piper Sandler
06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
MYL Mylan
$16.35 /

+0.39 (+2.44%)

06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
KR Kroger
$31.87 /

-0.945 (-2.88%)

06/19/20 Deutsche Bank
Kroger price target raised to $35 from $33 at Deutsche Bank
06/18/20 Wells Fargo
Kroger risk/reward 'compelling' after earnings selloff, says Wells Fargo
06/15/20 UBS
Kroger price target raised to $35 from $33 at UBS
06/11/20 Oppenheimer
Roku price target raised to $140 from $135 at Oppenheimer
CCL Carnival
$18.85 /

-0.24 (-1.26%)

06/19/20 Barclays
Carnival price target lowered to $18 from $53 at Barclays
06/18/20 William Blair
William Blair lowers 2020 estimates for Carnival after preliminary Q2 results
06/18/20 Stifel
Stifel sees Carnival shares coming under pressure after mixed business update
06/18/20
Fly Intel: Top five analyst downgrades
HTZ Hertz
$1.81 /

-0.195 (-9.75%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
FB Facebook
$235.94 /

+0.23 (+0.10%)

06/18/20 Morgan Stanley
Section 230 change likely a multi-year process, says Morgan Stanley
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
06/09/20 Goldman Sachs
Facebook price target raised to $250 from $220 at Goldman Sachs
06/08/20 Baird
Amazon.com price target raised to $2,750 from $2,550 at Baird
ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

06/18/20 JPMorgan
Enphase Energy selloff on short report overdone, says JPMorgan
06/18/20 Johnson Rice
Johnson Rice upgrades Enphase to Buy after short report, says pullback overdone
06/18/20 Johnson Rice
Enphase Energy upgraded to Buy from Accumulate at Johnson Rice
06/18/20 Cowen
Cowen sees 'compelling' buying opportunity after Enphase short report
T AT&T
$30.34 /

+0.08 (+0.26%)

06/15/20 Stephens
Electronic Arts seems like best fit as buyer for WB Interactive, says Stephens
06/15/20 Oppenheimer
EA makes 'most sense' as potential buyer of Warner gaming unit, says Oppenheimer
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
05/21/20 JPMorgan
Dish, AT&T's DirecTV combining could make sense, says JPMorgan
X U.S. Steel
$8.17 /

-1.2 (-12.81%)

06/09/20 GLJ Research
U.S. Steel upgraded to Hold from Sell at GLJ Research
03/23/20 BMO Capital
U.S. Steel price target lowered to $6 from $9 at BMO Capital
01/31/20 BMO Capital
U.S. Steel price target lowered to $10 from $14 at BMO Capital
01/14/20 Goldman Sachs
U.S. Steel reinstated with a Sell at Goldman Sachs
HUD Hudson
$5.79 /

-0.43 (-6.91%)

03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
02/04/20 UBS
Hudson downgraded to Neutral from Buy at UBS
11/05/19
Fly Intel: Top five analyst downgrades
11/05/19 BofA
Hudson downgraded to Underperform from Neutral at BofA/Merrill
X U.S. Steel
$8.17 /

-1.2 (-12.81%)

T AT&T
$30.34 /

+0.08 (+0.26%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

MYL Mylan
$16.35 /

+0.39 (+2.44%)

KR Kroger
$31.87 /

-0.945 (-2.88%)

HUD Hudson
$5.79 /

-0.43 (-6.91%)

HTZ Hertz
$1.81 /

-0.195 (-9.75%)

FB Facebook
$235.94 /

+0.23 (+0.10%)

ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

CCL Carnival
$18.85 /

-0.24 (-1.26%)

BIIB Biogen
$260.30 /

-21.26 (-7.55%)

  • 18
    Jun
X U.S. Steel
$8.17 /

-1.2 (-12.81%)

T AT&T
$30.34 /

+0.08 (+0.26%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

MYL Mylan
$16.35 /

+0.39 (+2.44%)

KR Kroger
$31.87 /

-0.945 (-2.88%)

HTZ Hertz
$1.81 /

-0.195 (-9.75%)

FB Facebook
$235.94 /

+0.23 (+0.10%)

ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

CCL Carnival
$18.85 /

-0.24 (-1.26%)

BIIB Biogen
$260.30 /

-21.26 (-7.55%)

X U.S. Steel
$8.17 /

-1.2 (-12.81%)

T AT&T
$30.34 /

+0.08 (+0.26%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

MYL Mylan
$16.35 /

+0.39 (+2.44%)

KR Kroger
$31.87 /

-0.945 (-2.88%)

HUD Hudson
$5.79 /

-0.43 (-6.91%)

HTZ Hertz
$1.81 /

-0.195 (-9.75%)

FB Facebook
$235.94 /

+0.23 (+0.10%)

ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

CCL Carnival
$18.85 /

-0.24 (-1.26%)

BIIB Biogen
$260.30 /

-21.26 (-7.55%)

X U.S. Steel
$8.17 /

-1.2 (-12.81%)

T AT&T
$30.34 /

+0.08 (+0.26%)

SPOT Spotify
$225.35 /

+25.51 (+12.77%)

MYL Mylan
$16.35 /

+0.39 (+2.44%)

KR Kroger
$31.87 /

-0.945 (-2.88%)

HTZ Hertz
$1.81 /

-0.195 (-9.75%)

FB Facebook
$235.94 /

+0.23 (+0.10%)

ENPH Enphase Energy
$45.69 /

+6.68 (+17.12%)

CCL Carnival
$18.85 /

-0.24 (-1.26%)

BIIB Biogen
$260.30 /

-21.26 (-7.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.